Insider Enric Alventosa Abril plans CRGO share sale (NASDAQ: CRGO)
Rhea-AI Filing Summary
CRGO insider plans additional stock sales under Rule 144. The notice states that Enric Alventosa Abril intends to sell 2,286 ordinary shares through Oppenheimer & Co. on or about 01/16/2026 on Nasdaq, with an aggregate market value of 6,172.20. The shares to be sold come from restricted stock units granted by the issuer on 09/06/2023 for 25,683 securities and on 07/29/2024 for 17,739 securities. The filing also lists recent sales over the prior three months, including 2,177 ordinary shares sold on 10/16/2025 and 3,063 shares sold on 11/26/2025 for gross proceeds of 9,865.80.
Positive
- None.
Negative
- None.
FAQ
What does the CRGO Form 144 filing disclose?
The Form 144 notice discloses that Enric Alventosa Abril plans to sell 2,286 ordinary shares of CRGO on Nasdaq through Oppenheimer & Co. Inc., with an aggregate market value of 6,172.20, under Rule 144.
How many CRGO shares are planned for sale in this Form 144?
The filing indicates a planned sale of 2,286 ordinary shares of CRGO, to be executed on or about 01/16/2026 via Oppenheimer & Co. Inc. on Nasdaq.
What is the source of the CRGO shares being sold by Enric Alventosa Abril?
The shares come from restricted stock units granted by the issuer, including 25,683 securities acquired on 09/06/2023 and 17,739 securities acquired on 07/29/2024, both listed as ordinary shares.
Which broker is handling the planned CRGO share sale?
The planned sale of 2,286 ordinary CRGO shares is to be handled by Oppenheimer & Co. Inc., located at 85 Broad St, New York, NY 10004, with trading on Nasdaq.
What recent CRGO share sales by Enric Alventosa Abril are disclosed?
The notice lists several sales of CRGO ordinary shares in the prior three months, including 2,177 shares sold on 10/16/2025 and 3,063 shares sold on 11/26/2025 for gross proceeds of 9,865.80.
What representation does the seller make in the CRGO Form 144?
By signing the notice, the seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, and acknowledges that intentional misstatements or omissions constitute federal criminal violations.